AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
sertindole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2435 | 106516-24-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an antipsychotic drug with selective inhibitory effect on mesolimbic dopaminergic neurons and balanced inhibitory effects on central dopamine D2 and serotonin 5HT2 receptors as well as on alpha1-adrenergic receptors
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 16 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 74 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 0.01 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 4.050 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.704 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 9.462 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 3.990 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 0.590 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 3.290 | % | High | 1 |
| herg | hERG pIC50 | 6.034 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.718 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 6.339 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.710 | % | High | 1 |
| kinase-safety-class | ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,MAP3K7,MAPK10,MAPK7,MET,NTRK2,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,TEK | 30 | |||
| kinase-selectivity-class | AXL,CAMK2D,DYRK1B,SIK2 | 4 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 8.279 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 7.907 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.630 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 18.707 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 1.470 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 6.180 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 1.640 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.830 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 0.773 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 23, 1996 | UK Medicines and Healthcare Products Regulatory Agency (MHRA) | H. Lundbeck A/S |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AE03 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Indole derivatives |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
| MeSH PA | D014150 | Antipsychotic Agents |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:37890 | α-adrenergic antagonist |
| CHEBI has role | CHEBI:37955 | H<small><sub>1</sub></small>-receptor antagonist |
| CHEBI has role | CHEBI:48279 | serotonergic antagonist |
| CHEBI has role | CHEBI:65191 | second generation antipsychotic |
Related Drugs by ATC class:
N05AE Indole derivatives 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.74 | acidic |
| pKa2 | 8.5 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 9.35 | CHEMBL | SCIENTIFIC LITERATURE | |||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 9.22 | CHEMBL | SCIENTIFIC LITERATURE | |||
| 5-hydroxytryptamine receptor 2C | GPCR | INVERSE AGONIST | Ki | 9.70 | CHEMBL | SCIENTIFIC LITERATURE | |||
| D(1A) dopamine receptor | GPCR | Ki | 6.68 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.19 | PDSP | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 8.57 | CHEMBL | |||||
| Multidrug resistance protein 1 | Transporter | IC50 | 5.19 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 7.48 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 8.30 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | Ki | 7.55 | PDSP | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 8.75 | PDSP | |||||
| D(3) dopamine receptor | GPCR | Ki | 8.59 | CHEMBL | |||||
| Histamine H1 receptor | GPCR | Ki | 9.29 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.57 | PDSP | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 7.25 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | ANTAGONIST | Ki | 7.20 | IUPHAR | ||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 6.35 | PDSP | |||||
| D(4) dopamine receptor | GPCR | Ki | 7.96 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1F | GPCR | ANTAGONIST | Ki | 6.40 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 1E | GPCR | ANTAGONIST | Ki | 6.40 | IUPHAR | ||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 6.35 | PDSP | |||||
| Beta-1 adrenergic receptor | GPCR | Ki | 5.30 | PDSP | |||||
| Beta-2 adrenergic receptor | GPCR | Ki | 5.30 | PDSP | |||||
| Alpha-1A adrenergic receptor | GPCR | IC50 | 8.47 | CHEMBL | |||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 9.18 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Ki | 9.35 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 9.70 | CHEMBL | |||||
| D(1A) dopamine receptor | GPCR | Ki | 7.92 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 9.29 | CHEMBL | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 9.43 | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 9.48 | CHEMBL | |||||
| Adrenergic receptor alpha-1 | GPCR | Ki | 8.85 | CHEMBL | |||||
| Serotonin 2 (5-HT2) receptor | GPCR | IC50 | 9.41 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4025271 | VUID |
| N0000179296 | NUI |
| D00561 | KEGG_DRUG |
| 4025271 | VANDF |
| C0084528 | UMLSCUI |
| CHEBI:9122 | CHEBI |
| CHEMBL12713 | ChEMBL_ID |
| DB06144 | DRUGBANK_ID |
| C066304 | MESH_SUPPLEMENTAL_RECORD_UI |
| 98 | IUPHAR_LIGAND_ID |
| 6455 | INN_ID |
| GVV4Z879SP | UNII |
| 60149 | PUBCHEM_CID |
| 152894 | RXNORM |
| 006145 | NDDF |
| 321603004 | SNOMEDCT_US |
| 418732002 | SNOMEDCT_US |
| GVV4Z879SP | INXIGHT DRUGS |
Pharmaceutical products:
None